The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna P, Farahdel E, Potenza M, Crowley M. The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder. Expert Opinion On Pharmacotherapy 2023, 24: 835-847. PMID: 37074259, PMCID: PMC10197951, DOI: 10.1080/14656566.2023.2199921.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSelective norepinephrine reuptake inhibitorGeneralized anxiety disorderAnxiety disordersReuptake inhibitorsPediatric generalized anxiety disorderBetter long-term outcomesSecond-line treatmentNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsFirst-line interventionLong-term outcomesCombination of psychotherapyPrevalent psychiatric disordersEvidence-based statePediatric anxiety disordersArt pharmacotherapyModerate effect sizeFunctional outcomeEarly recognitionMood disordersElevated riskPsychiatric disordersBetter outcomesElectronic databases